With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.875444-08-9,(4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one,as a common compound, the synthetic route is as follows.
875444-08-9, iNTERMEDIATE 29 (4S,5R?)-5- 13 ,5-Bis(trifluoromethyl)phenyl] -3- F(5-bromo-2-chloropyridin-4-yl)methyll -4-methyl- 1 ,3-oxazolidin-2-oneA solution of (4S,5R)-5- [3 ,5-bis(trifluoromethyl)phenyl] -4-methyl- 1,3 -oxazolidin-2-one(INTERMEDIATE 4, 1.305 g, 4.17 mmol) in 30 mL of DMF was cooled to -20C. NaHMDS(1.0 M, 4.17 ml, 4.17 mmol) was added and the reaction was stirrred at -20C for 20 minutes.Next, a solution of (5-bromo-2-chloropyridin-4-yl)methyl methanesulfonate (II?1TERMEDIATE28, 1.2522 g, 4.17 mmol) in 5 mL of DMF was added and the solution turned brown. Thereaction was warmed to 0C by switching to an ice/water bath and the reaction stirred for an additional 30 minutes, at which time an LCMS aliquot confirmed the reaction was complete. It was quenched with aqueous NaHCO3. The reaction was extracted with ethyl acetate, then washed with aqueous NaHCO3 and brine, dried with Na2SO4, filtered and the filtrate was concentrated. The crude oil was purified by silica gel chromatography to give the titledcompound as an off-white solid. ?H NMR (CDC13, 500 MHz): 8.52 (s, 1H), 7.92 (s, 1H), 7.80 (s, 2H), 7.36 (s, 1H), 5.81 (d, 1H), 4.78 (d, 1H), 4.34 (d, 1H), 4.17 (m, 1H), 0.82 (d, 3H).
875444-08-9 (4S,5R)-5-(3,5-Bis(trifluoromethyl)phenyl)-4-methyloxazolidin-2-one 23583229, aoxazolidine compound, is more and more widely used in various fields.
Reference£º
Patent; MERCK SHARP & DOHME CORP.; ACTON, John, J., III; YE, Feng; VACHAL, Petr; SHA, Deyou; DROPINSKI, James, F.; CHU, Lin; ONDEYKA, Debra; KIM, Alexander, J.; COLANDREA, Vincent, J.; ZANG, Yi; ZHANG, Fengqi; DONG, Guizhen; WO2013/165854; (2013); A1;,
Oxazolidine – Wikipedia
Oxazolidine | C3H7NO – PubChem